December 18, 2020 -- The European Commission (EC) has exercised an option to purchase an additional 80 million doses of Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, bringing the EC's total order to 160 million doses.
The first deliveries of the doses are expected in Europe in early 2021, following regulatory approval by the European Medicines Agency (EMA). Regulatory approval is subject to a positive opinion by the EMA's Committee for Medicinal Products for Human Use (CHMP) and the European Commission's decision for conditional marketing authorization. The CHMP meeting is planned for January 6, 2021.
Moderna has received orders for its vaccine candidate from the U.S. (200 million, with the option for an additional 300 million), the European Union (160 million), Japan (50 million), Canada (40 million, with the option for an additional 16 million), Switzerland (7.5 million), the U.K. (7 million), Israel (6 million), and others.
Copyright © 2020 scienceboard.net